E0 ConsensusModerate confidencePEM not requiredGuidelinePeer-reviewedMachine draft
EULAR evidence-based recommendations for the management of fibromyalgia syndrome.
Carville, S F, Arendt-Nielsen, L, Bliddal, H et al. · Annals of the rheumatic diseases · 2008 · DOI
Quick Summary
European medical experts reviewed research on how to treat fibromyalgia, a condition causing widespread pain and fatigue. They looked at studies of different treatments—medicines and therapies like exercise and counseling—to see which ones worked best. Based on the strongest evidence available, they created 9 recommendations to help doctors manage fibromyalgia.
Why It Matters
While this study explicitly excluded ME/CFS patients, its systematic review framework and treatment categorization (antidepressants, analgesics, exercise, cognitive behavioral therapy, education, dietary interventions) provide a methodological blueprint relevant to ME/CFS research. Understanding how fibromyalgia recommendations were developed—and notably, why ME/CFS was excluded—highlights the need for parallel evidence synthesis specifically for ME/CFS management.
Observed Findings
- 146 studies met initial eligibility criteria for fibromyalgia management research.
- 98 studies (39 pharmacological and 59 non-pharmacological) were included in final recommendation summary tables after quality screening.
- Many included studies had small sample sizes and insufficient data quality.
- Treatment categories identified included antidepressants, analgesics, 'other pharmacological' interventions, exercise, cognitive behavioral therapy, education, dietary interventions, and 'other non-pharmacological' approaches.
- Nine recommendations for fibromyalgia management were successfully developed.
Inferred Conclusions
- A systematic evidence-based approach to fibromyalgia management requires screening studies for methodological quality, particularly randomization, blinding, and allocation concealment.
- When high-quality trial evidence is insufficient, expert consensus methods can supplement evidence synthesis to develop clinical recommendations.
- Fibromyalgia treatment spans multiple modalities; no single pharmacological or non-pharmacological approach is universally supported by strong evidence alone.
Remaining Questions
- Why were ME/CFS patients specifically excluded from this fibromyalgia management review, and what are the clinical/biological justifications for this distinction?
What This Study Does Not Prove
This study does not establish that fibromyalgia treatment recommendations apply to ME/CFS, as the authors explicitly excluded ME/CFS patients from their analysis. The study cannot prove causation for any treatment-outcome relationships; it synthesizes existing trial data without establishing mechanisms. Small sample sizes in many included studies limit the strength of individual treatment recommendations.
Tags
Symptom:PainFatigue
Method Flag:Weak Case DefinitionSmall Sample
Metadata
- DOI
- 10.1136/ard.2007.071522
- PMID
- 17644548
- Review status
- Machine draft
- Evidence level
- Established evidence from major reviews, guidelines, or evidence maps
- Last updated
- 10 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →